Patent ID: 8586615

Claim:
A method of treating a condition, disease, or disorder in a patient implicated by CFTR wherein the disease or disorder is selected from cystic fibrosis, hereditary emphysema, chronic obstructive pulmonary disease (COPD), or dry-eye disease, comprising the step of administering to said patient a compound according to formula I or formula II: or a pharmaceutically acceptable salt thereof, wherein: each R X is independently hydrogen, halo, CF 3 , C1-C4 alkyl, or —OC1-C4 alkyl; provided that both R X are not simultaneously hydrogen; or the two R X , taken together form ring (a): X is CH 2 , CF 2 , CH 2 —CH 2 , or CF 2 —CF 2 ; ring A is 3-7 membered monocyclic cycloalkyl ring; R AA and R BB , taken together with the nitrogen atom, form a pyrrolidinyl ring substituted with OR′; R′ is hydrogen or C1-C6 aliphatic, wherein up to two carbon units of said aliphatic are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR—, —CONRNR—, —CO 2 —, —OCO—, —NRCO 2 —, —O—, —NRCONR—, —OCONR—, —NRNR, —NRNRCO—, —NRCO—, —S—, —SO, —SO 2 —, —NR—, —SO 2 NR—, NRSO 2 —, or —NRSO 2 NR—; R is hydrogen or C1-C6 aliphatic; Z is an electron withdrawing substituent; and q is 0-3.